Table 2

Secondary end points 20 days after enrolment and change from baseline values according to treatment group

At day 20Crude change from baseline
End pointCorticosteroid* (No of missing data)Placebo* (No of missing data)Corticosteroid (n=43)Placebo (n=42)Treatment effect (95% CI)
*Missing data are handled by applying an LOCF procedure (last observation carried forward). Results are expressed as means (SD) calculated once the LOCF procedure has been applied. We also state the number of missing data in each group.
†A positive value means improvement.
Pain VAS (mm)28.0 (24.8)(2)39.8 (21.9)(8)−28.3 (28.8)−17.4 (28.5)−10.9(−23.1 to 1.3)
Schober’s test (cm)†3.06 (0.80)(20)3.00 (0.97)(24)0.63 (1.11)0.46 (1.09)0.18(−0.29 to 0.64)
SLR test (degree)†61.2 (22.2)(4)60.5 (20.6)(10)13.7 (22.9)11.7 (16.3)2.1(−6.4 to 10.5)
Dallas pain questionnaire:
    Daily activities40.9 (27.9)(5)49.4 (24.2)(8)−23.2 (29.1)−16.8 (27.4)−6.3(−18.3 to 5.7)
    Work-leisure activities49.7 (33.3)(8)61.6 (26.9)(10)−21.2 (33.0)−13.9 (30.3)−7.2(−20.7 to 6.2)
    Anxiety-depression20.7 (23.8)(5)30.3 (27.3)(9)−7.0 (35.0)−3.8 (25.4)−3.2(−16.2 to 9.8)
    Social interest18.0 (19.6)(5)25.2 (19.1)(9)−10.7 (25.0)−0.2 (19.7)−10.5(−20.0 to −0.9)
Roland-Morris index10.9 (5.8)(6)11.7 (5.0)(8)−3.6 (6.9)−1.8 (6.3)−1.8(−4.6 to 1.0)